Syndrome d’hyperémèse cannabique : à propos de 6 cas

Bertolino, J.; Abdo, L.; Khau, D.; Meckenstock, R.; Sautereau, N.; Jean, E.; Greder-Belan, A.; Francès, Y.; Cabané, J.; Granel, B.

doi:10.1016/j.revmed.2014.11.012

Cited by 9 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All included studies, with the exception of the survey, reported at least one GIT symptom experienced in adult cannabis users. Reported GIT symptoms included nausea, vomiting, diarrhoea, abdominal pain/distension, constipation, loss of appetite, dehydration, adult intussusception (AI), and weight loss [8, 10, 17‒27]. The severity of the symptoms varied, ranging from mild occurrences to requiring emergency department admission.…”

Section: Resultsmentioning

confidence: 99%

“…By synthesising and analysing the available evidence, this review identified several findings that can potentially contribute to our understanding of the impact of cannabis on gastrointestinal health in the adult population. All included studies, with the exception of the survey, reported some type of GIT symptoms experienced in cannabis users ranging from nausea, vomiting, diarrhoea, abdominal pain, to AI [8, 10, 17‒27].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cannabis-Induced Gastrointestinal Tract Symptoms in the Adult Population: A Systematic Review

Senderovich,

Meaney,

Vashishtha

2024

Med Princ Pract

View full text Add to dashboard Cite

Objective: Cannabinoid usage is widespread in the self-management of various medical ailments. However, adverse effects have been reported with use, especially pertaining to the gastrointestinal system in adults and aged patients. These range from nausea, vomiting, bloating, or abdominal pain. This systematic review of previously reported cannabis-induced gastrointestinal symptoms in the adult population from the literature provides an analysis of relevant data to enhance knowledge and awareness of this topic. Methods: PubMed, Ovid MEDLINE, Cochrane Central, EMBASE and Google Scholar databases were searched for relevant studies published from inception to March 2023. Results: The search yielded 598 results, of which 13 were deemed relevant and underwent further review. These included two systematic reviews, one retrospective cohort study, one retrospective chart review, two cross-sectional studies, one survey, and six case reports. The Cochrane Risk Tool for bias analysis was applied where relevant. The total number of people in the studies selected for analysis was 79, 779. Twelve out of the thirteen included studies reported some type of gastrointestinal tract symptoms experienced in medical and/or recreational cannabis users ranging from nausea, vomiting, diarrhoea, abdominal pain, to adult intussusception. Conclusion: Potential limitations include small sample sizes, variation in research methodologies, varied studied designs, and limited availability of data on specific populations such as geriatric users. Further research is warranted to add to current evidence pertaining to this emerging topic of significance, fill the broad knowledge gaps and contribute to evidence-based guidelines for healthcare professionals, ensuring safe prescribing practices and provision of quality care.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Cannabis-Induced Gastrointestinal Tract Symptoms in the Adult Population: A Systematic Review

Senderovich,

Meaney,

Vashishtha

2024

Med Princ Pract

View full text Add to dashboard Cite

show abstract

“…During consultation, psychiatric advice was requested for 18% of patients, essentially for fear. In previous French case reports [7,8,18], 17.2% of patients suffered from anxiety. Being anxious at the beginning of an attack of hyperemesis could contribute to its intensity.…”

Section: Discussionmentioning

confidence: 99%

“…About 10 case reports were published in the United States between 2010 and 2015 each covering 4–8 cases [3–5], and three series were published in France between 2013 and 2016 each including 6 or 7 cases [6–8]. In June 2018, the emergency department in San Diego, California, edited a Novel Model Treatment Guideline, in order to improve symptomatic treatment of these patients [9].…”

Section: Introductionmentioning

confidence: 99%

Cannabinoid hyperemesis syndrome in two French emergency departments: a prospective cohort

Weiss

Torrents

Verhamme

et al. 2020

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Chronic cannabis use can be associated with uncontrollable vomiting and abdominal pain. Diagnostic criteria for cannabinoid hyperemesis syndrome (CHS) were defined in 2012 by Simonetto et al. The objectives of this study were to describe the prevalence of CHS, the patients' epidemiological characteristics, and to show the difficulties encountered in caring for these patients in emergency departments, the extent of health care and an unsuitable follow‐up in general practices. A prospective cohort of patients with CHS was recruited among a target population of patients leaving the adult emergency services of the Marseille hospitals Nord and La Timone between October 2017 and July 2018, with abdominal pain syndrome of unidentified etiology. Inclusion criteria for the CHS cohort were chronic cannabis use associated with nausea and vomiting. There were 48 patients included in the CHS cohort who took cannabis daily, in a target population of 2 848 patients (i.e. 1.6%). A hot shower was the most effective symptomatic treatment in 54.2% of cases. Patients suffering from CHS spent significantly more hours in emergency departments (11 vs. 6.5), and, on average, visits were more frequent (4.9 vs. 3). 20.3% of them were hospitalized to continue pain medication. Once out of hospital, follow‐up was limited, and weaning off cannabis, the only etiological treatment, was difficult to set up. Informing patients about CHS is essential, and a hot shower could be systematically proposed, thus limiting an unnecessary extent of health care. CHS is genuine, medical staff should be made aware of it in occupational training, and it should be seriously considered in health policies.

show abstract

“…While early identification of CHS and supportive treatment helps improve in most cases, limited response to abortive antiemetic agents is often noted in previous literature [77][78][79]. There is considerable overlap in the treatment of CHS in previous literature.…”

Section: Management Of Cannabis Hyperemesis Syndromementioning

confidence: 99%

Endocannabinoid system and cannabis hyperemesis syndrome: a narrative update

Perisetti

Goyal

2020

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Cannabis use has been increasing in the United States and throughout the world. It is derived from one of the earliest plants cultivated by humans -Cannabis sativa. Cannabis (also called marijuana) is the most commonly used psychoactive substance worldwide. The cannabis plant has more than 400 chemicals, of which more than 100 cannabinoids (such as cannabigerol, cannabidiol, and cannabinol) have been identified. The endocannabinoid system (ECS) plays an essential role in the effects of cannabis on end organs. Although cannabis use has been reported for many decades, some of its unique adverse effects of nausea, vomiting, and abdominal pain, termed as cannabis hyperemesis syndrome (CHS), were noted recently. The legal status of cannabis in the United States has been rapidly changing from state to state. The incidence of CHS is expected to rise with rising access to cannabis in the United States. Furthermore, CHS is frequently underdiagnosed due to a lack of uniform criteria, subjective nature of symptoms, and overlap with cyclical vomiting syndrome (CVS). Understanding the ECS and its role in biphasic response (proemetic and antiemetic) of CHS is critical to explain its pathophysiology. As the use of cannabis increases globally, awareness of CHS is warranted for early recognition and prompt treatment to avoid complications. We describe the putative mechanism of CHS with an overview of the clinical features in these patients. Furthermore, we highlight the differences between CHS and CVS with important differentials to consider. We provide a narrative update on the current evidence on CHS pathophysiology, diagnosis, treatment, and identifying research gaps.

show abstract

Syndrome d’hyperémèse cannabique : à propos de 6 cas

Cited by 9 publications

References 7 publications

Cannabis-Induced Gastrointestinal Tract Symptoms in the Adult Population: A Systematic Review

Cannabis-Induced Gastrointestinal Tract Symptoms in the Adult Population: A Systematic Review

Cannabinoid hyperemesis syndrome in two French emergency departments: a prospective cohort

Endocannabinoid system and cannabis hyperemesis syndrome: a narrative update

Contact Info

Product

Resources

About